Oncotelic Therapeutics, Inc. 8-K Filing
Ticker: OTLC · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0000908259
| Field | Detail |
|---|---|
| Company | Oncotelic Therapeutics, Inc. (OTLC) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Oncotelic Therapeutics, Inc. (ticker: OTLC) to the SEC on Apr 2, 2026.
How long is this filing?
Oncotelic Therapeutics, Inc.'s 8-K filing is 3 pages with approximately 798 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 798 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2026-04-02 09:15:10
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 218KB
- ex99-1.htm (EX-99.1) — 16KB
- ex10-1_001.jpg (GRAPHIC) — 42KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-26-014831.txt ( ) — 558KB
- otlc-20260331.xsd (EX-101.SCH) — 3KB
- otlc-20260331_lab.xml (EX-101.LAB) — 33KB
- otlc-20260331_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description Filed on 10.1 Joint Development, Manufacturing and Licensing Agreement 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oncotelic Therapeutics, Inc. Date: April 2, 2026 By: /s/ Vuong Trieu Vuong Trieu Chief Executive Officer -3-